Stocktoria
PolyPid Ltd. PYPD
Nasdaq · XNAS · stock · Surgical & Medical Instruments & Apparatus · website · IPO 2020-06-26
PolyPid Ltd. financials (annual, from 10-K)
| Metric | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 |
|---|---|---|---|---|---|
| R&D expense | $23.8M | $22.8M | $16.1M | $28.0M | $30.6M |
| Operating income | -$33.0M | -$28.0M | -$22.9M | -$38.9M | -$43.1M |
| Income tax | $5,000 | $42,000 | $69,000 | $129,000 | — |
| Net income | -$34.2M | -$29.0M | -$23.9M | -$39.6M | -$42.6M |
| EPS (diluted) | $2.09 | $4.91 | $16.93 | $61.09 | $68.27 |
| Operating cash flow | -$27.9M | -$22.0M | -$17.2M | -$34.3M | -$32.4M |
| Free cash flow | -$28.1M | -$22.0M | -$17.4M | -$36.1M | -$35.0M |
| Cash & equivalents | $6.4M | $15.6M | $5.3M | $8.6M | $9.8M |
| Total assets | $22.3M | $25.2M | $15.4M | $26.0M | $44.2M |
| Shareholders' equity | $11.0M | $7.7M | -$2.1M | $5.8M | $36.0M |
Source: SEC EDGAR filings · CIK 0001611842 · as of 2025-12-31. Facts from filings plus Stocktoria's own computed scores — not investment advice.